• 2024
  Jeger-Madiot R, Planas D, Staropoli I, Debarnot H, Kervevan J, Mary H, Collina C, Fonseca BF, Robinot R, Gellenoncourt S, Schwartz O, Ewart L, Bscheider M, Gobaa S, Chakrabarti LA, Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting., J Exp Med 2024 Oct; 221(10): .
• 2024
  Planchais C, Fernández I, Chalopin B, Bruel T, Rosenbaum P, Beretta M, Dimitrov JD, Conquet L, Donati F, Prot M, Porrot F, Planas D, Staropoli I, Guivel-Benhassine F, Baquero E, van der Werf S, Haouz A, Simon-Lorière E, Montagutelli X, Maillère B, Rey FA, Guardado-Calvo P, Nozach H, Schwartz O, Mouquet H, Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2., iScience 2024 Jul; 27(7): 110354.
• 2024
  Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S, Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O, Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion., Nat Commun 2024 Mar; 15(1): 2254.
• 2024
  Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, Prot M, Guivel-Benhassine F, Lemoine F, Enouf V, Simon-Loriere E, Mouquet H, Rameix-Welti MA, Schwartz O, Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies., Pathog Immun 2024 ; 10(1): 1-11.
• 2023
  Bolland W, Michel V, Planas D, Hubert M, Staropoli I, Guivel-Benhassine F, Porrot F, N'Debi M, Rodriguez C, Fourati S, Prot M, Planchais C, Hocqueloux L, Simon-Lorière E, Mouquet H, Prazuck T, Pawlotsky J-M, Bruel T, Schwartz O, Buchrieser J, High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1., J Virol 2023 Dec; (): e0135123.
• 2023
  Znaidia M, de Souza-Angelo Y, Létoffé S, Staropoli I, Grzelak L, Ghigo JM, Schwartz O, Casartelli N, Exposure to Secreted Bacterial Factors Promotes HIV-1 Replication in CD4+ T Cells., Microbiol Spectr 2023 Apr 13; 11(2): e0431322.
• 2023
  Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, Puech J, Saliba M, Sahraoui R, Fémy F, Morel N, Dufloo J, Sanjuán R, Mouquet H, André E, Hocqueloux L, Simon-Loriere E, Veyer D, Prazuck T, Péré H, Schwartz O, , Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies., Nat Commun 2023 Feb; 14(1): 824.
• 2023
  Kervevan J, Staropoli I, Slama D, Jeger-Madiot R, Donnadieu F, Planas D, Pietri MP, Loghmari-Bouchneb W, Alaba Tanah M, Robinot R, Boufassa F, White M, Salmon-Ceron D, Chakrabarti LA, Divergent adaptive immune responses define two types of long COVID., Front Immunol 2023 ; 14(): 1221961.
• 2022
  Bruel T, Stéfic K, Nguyen Y, Toniutti D, Staropoli I, Porrot F, Guivel-Benhassine F, Bolland WH, Planas D, Hadjadj J, Handala L, Planchais C, Prot M, Simon-Lorière E, André E, Baele G, Cuypers L, Mouthon L, Mouquet H, Buchrieser J, Sève A, Prazuck T, Maes P, Terrier B, Hocqueloux L, Schwartz O, , Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies., Cell Rep Med 2022 Nov; (): 100850.
• 2022
  Planas D, Staropoli I, Porot F, Guivel-Benhassine F, Handala L, Prot M, Bolland WH, Puech J, Péré H, Veyer D, Sève A, Simon-Lorière E, Bruel T, Prazuck T, Stefic K, Hocqueloux L, Schwartz O, , Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection., Med (N Y) 2022 Dec; 3(12): 838-847.e3.
• 2022
  Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, Guivel-Benhassine F, Attia M, Pelleau S, Woudenberg T, Duru C, Koffi AD, Castelain S, Fernandes-Pellerin S, Jolly N, De Facci LP, Roux E, Ungeheuer MN, Van Der Werf S, White M, Schwartz O, Fontanet A, Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study., EClinicalMedicine 2022 Sep; 51(): 101576.
• 2022
  Planchais C, Fernández I, Bruel T, de Melo GD, Prot M, Beretta M, Guardado-Calvo P, Dufloo J, Molinos-Albert LM, Backovic M, Chiaravalli J, Giraud E, Vesin B, Conquet L, Grzelak L, Planas D, Staropoli I, Guivel-Benhassine F, Hieu T, Boullé M, Cervantes-Gonzalez M, Ungeheuer MN, Charneau P, van der Werf S, Agou F, , , Dimitrov JD, Simon-Lorière E, Bourhy H, Montagutelli X, Rey FA, Schwartz O, Mouquet H, Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2., J Exp Med 2022 Jul; 219(7): .
• 2022
  Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, Guivel-Benhassine F, Porrot F, Bolland WH, Nguyen Y, Casadevall M, Charre C, Péré H, Veyer D, Prot M, Baidaliuk A, Cuypers L, Planchais C, Mouquet H, Baele G, Mouthon L, Hocqueloux L, Simon-Loriere E, André E, Terrier B, Prazuck T, Schwartz O, Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies., Nat Med 2022 Jun; 28(6): 1297-1302.
• 2022
  Saunders N, Planas D, Bolland WH, Rodriguez C, Fourati S, Buchrieser J, Planchais C, Prot M, Staropoli I, Guivel-Benhassine F, Porrot F, Veyer D, Péré H, Robillard N, Saliba M, Baidaliuk A, Seve A, Hocqueloux L, Prazuck T, Rey FA, Mouquet H, Simon-Lorière E, Bruel T, Pawlotsky JM, Schwartz O, Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2., EBioMedicine 2022 Mar; 77(): 103934.
• 2022
  Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Péré H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Martí-Carreras J, Cuypers L, Sève A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, André E, Schwartz O, Considerable escape of SARS-CoV-2 Omicron to antibody neutralization., Nature 2022 Feb; 602(7898): 671-675.
• 2022
  Claireaux M, Robinot R, Kervevan J, Patgaonkar M, Staropoli I, Brelot A, Nouël A, Gellenoncourt S, Tang X, Héry M, Volant S, Perthame E, Avettand-Fenoël V, Buchrieser J, Cokelaer T, Bouchier C, Ma L, Boufassa F, Hendou S, Libri V, Hasan M, Zucman D, de Truchis P, Schwartz O, Lambotte O, Chakrabarti LA, , Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry., Nat Commun 2022 Jan; 13(1): 521.
• 2021
  Monel B, Planas D, Grzelak L, Smith N, Robillard N, Staropoli I, Goncalves P, Porrot F, Guivel-Benhassine F, Guinet ND, Rodary J, Puech J, Euzen V, Bélec L, Orvoen G, Nunes L, Moulin V, Fourgeaud J, Wack M, Imbeaud S, Campagne P, Duffy D, Santo JPD, Bruel T, Péré H, Veyer D, Schwartz O, , Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study., EBioMedicine 2021 Nov; 73(): 103637.
• 2021
  Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization., Nature 2021 Aug; 596(7871): 276-280.
• 2021
  Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, Barnabei L, Corneau A, Da Meda L, Allayous C, Baroudjian B, Jebali M, Herms F, Grzelak L, Staropoli I, Calmettes V, Hadjadj J, Peyrony O, Cassius C, LeGoff J, Kramkimel N, Aractingi S, Fontes M, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbé C, , Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection., Sci Adv 2021 08; 7(34): .
• 2021
  Dufloo J, Grzelak L, Staropoli I, Madec Y, Tondeur L, Anna F, Pelleau S, Wiedemann A, Planchais C, Buchrieser J, Robinot R, Ungeheuer MN, Mouquet H, Charneau P, White M, Lévy Y, Hoen B, Fontanet A, Schwartz O, Bruel T, Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies., Cell Rep Med 2021 May; 2(5): 100275.
• 2021
  Fontanet A, Tondeur L, Grant R, Temmam S, Madec Y, Bigot T, Grzelak L, Cailleau I, Besombes C, Ungeheuer MN, Renaudat C, Perlaza BL, Arowas L, Jolly N, Pellerin SF, Kuhmel L, Staropoli I, Huon C, Chen KY, Crescenzo-Chaigne B, Munier S, Charneau P, Demeret C, Bruel T, Eloit M, Schwartz O, Hoen B, SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020., Euro Surveill 2021 Apr; 26(15): .
• 2021
  Galmiche S, Bruel T, Madec Y, Tondeur L, Grzelak L, Staropoli I, Cailleau I, Ungeheuer MN, Renaudat C, Fernandes Pellerin S, Hoen B, Schwartz O, Fontanet A, , Characteristics Associated with Olfactory and Taste Disorders in COVID-19., Neuroepidemiology 2021 ; 55(5): 381-386.
• 2020
  Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouénan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Créach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S, A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations., Sci Transl Med 2020 Sep; 12(559): .
• 2020
  Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, Staropoli I, Anna F, Souque P, Fernandes-Pellerin S, Jolly N, Renaudat C, Ungeheuer MN, Schmidt-Mutter C, Collongues N, Bolle A, Velay A, Lefebvre N, Mielcarek M, Meyer N, Rey D, Charneau P, Hoen B, De Seze J, Schwartz O, Fontanet A, , Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France., EBioMedicine 2020 Sep; 59(): 102915.
• 2018
  Colin P, Zhou Z, Staropoli I, Garcia-Perez J, Gasser R, Armani-Tourret M, Benureau Y, Gonzalez N, Jin J, Connell BJ, Raymond S, Delobel P, Izopet J, Lortat-Jacob H, Alcami J, Arenzana-Seisdedos F, Brelot A, Lagane B, CCR5 structural plasticity shapes HIV-1 phenotypic properties, PLoS Pathog. 2018 Dec;14(12):e1007432.
• 2016
  Benureau Y, Colin P, Staropoli I, Gonzalez N, Garcia-Perez J, Alcami J, Arenzana-Seisdedos F, Lagane B, Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins, J. Virol. Methods 2016 Oct;236:184-95.
• 2015
  Garcia-Perez J, Staropoli I, Azoulay S, Heinrich JT, Cascajero A, Colin P, Lortat-Jacob H, Arenzana-Seisdedos F, Alcami J, Kellenberger E, Lagane B, A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity, Retrovirology 2015;12:50.
• 2014
  Jin J, Colin P, Staropoli I, Lima-Fernandes E, Ferret C, Demir A, Rogée S, Hartley O, Randriamampita C, Scott MG, Marullo S, Sauvonnet N, Arenzana-Seisdedos F, Lagane B, Brelot A, Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry, J. Biol. Chem. 2014 Jul;289(27):19042-52.
• 2013
  Colin P, Bénureau Y, Staropoli I, Wang Y, Gonzalez N, Alcami J, Hartley O, Brelot A, Arenzana-Seisdedos F, Lagane B, HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines, Proc. Natl. Acad. Sci. U.S.A. 2013 Jun;110(23):9475-80.
• 2010
  Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, Arenzana-Seisdedos F, Lagane B, New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection, J. Biol. Chem. 2011 Feb;286(7):4978-90.
• 2008
  Rueda P, Balabanian K, Lagane B, Staropoli I, Chow K, Levoye A, Laguri C, Sadir R, Delaunay T, Izquierdo E, Pablos JL, Lendinez E, Caruz A, Franco D, Baleux F, Lortat-Jacob H, Arenzana-Seisdedos F, The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins, PLoS ONE 2008;3(7):e2543.
• 2007
  Lozach PY, Burleigh L, Staropoli I, Amara A, The C type lectins DC-SIGN and L-SIGN: receptors for viral glycoproteins, Methods Mol. Biol. 2007;379:51-68.
• 2006
  Burleigh L, Lozach PY, Schiffer C, Staropoli I, Pezo V, Porrot F, Canque B, Virelizier JL, Arenzana-Seisdedos F, Amara A, Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells, J. Virol. 2006 Mar;80(6):2949-57.
• 2005
  Nal B, Chan C, Kien F, Siu L, Tse J, Chu K, Kam J, Staropoli I, Crescenzo-Chaigne B, Escriou N, van der Werf S, Yuen KY, Altmeyer R, Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E, J. Gen. Virol. 2005 May;86(Pt 5):1423-34.
• 2005
  Lagane B, Ballet S, Planchenault T, Balabanian K, Le Poul E, Blanpain C, Percherancier Y, Staropoli I, Vassart G, Oppermann M, Parmentier M, Bachelerie F, Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis, Mol. Pharmacol. 2005 Jun;67(6):1966-76.
• 2003
  Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, Schwartz O, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R, DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2, J. Biol. Chem. 2003 May;278(22):20358-66.
• 2002
  Chanel C, Staropoli I, Baleux F, Amara A, Valenzuela-Fernandez A, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R, Low levels of co-receptor CCR5 are sufficient to permit HIV envelope-mediated fusion with resting CD4 T cells, AIDS 2002 Nov;16(17):2337-40.
• 2002
  Percherancier Y, Lagane B, Planchenault T, Staropoli I, Altmeyer R, Virelizier JL, Arenzana-Seisdedos F, Hoessli DC, Bachelerie F, HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains, J. Biol. Chem. 2003 Jan;278(5):3153-61.
• 2002
  Valenzuela-Fernández A, Planchenault T, Baleux F, Staropoli I, Le-Barillec K, Leduc D, Delaunay T, Lazarini F, Virelizier JL, Chignard M, Pidard D, Arenzana-Seisdedos F, Leukocyte elastase negatively regulates Stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4, J. Biol. Chem. 2002 May;277(18):15677-89.
• 2000
  Staropoli I, Chanel C, Girard M, Altmeyer R, Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate, J. Biol. Chem. 2000 Nov;275(45):35137-45.
• 1997
  Staropoli I, Frenkiel MP, Mégret F, Deubel V, Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice, Vaccine 1997 Dec;15(17-18):1946-54.
• 1996
  Staropoli I, Clément JM, Frenkiel MP, Hofnung M, Deubel V, Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein, J. Virol. Methods 1996 Feb;56(2):179-89.
• 1994
  Delenda C, Staropoli I, Frenkiel MP, Cabanié L, Deubel V, Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice, J. Gen. Virol. 1994 Jul;75 ( Pt 7):1569-78.